Alector Inc (ALEC) - Total Assets
Based on the latest financial reports, Alector Inc (ALEC) holds total assets worth $293.24 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Alector Inc investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Alector Inc - Total Assets Trend (2016–2025)
This chart illustrates how Alector Inc's total assets have evolved over time, based on quarterly financial data. Check Alector Inc (ALEC) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Alector Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Alector Inc's total assets of $293.24 Million consist of 90.9% current assets and 9.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 22.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Alector Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Alector Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alector Inc's current assets represent 90.9% of total assets in 2025, a decrease from 94.6% in 2016.
- Cash Position: Cash and equivalents constituted 22.4% of total assets in 2025, down from 94.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Alector Inc Competitors by Total Assets
Key competitors of Alector Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Alector Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.83 | 3.40 | 5.85 |
| Quick Ratio | 3.83 | 3.40 | 5.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $196.95 Million | $299.76 Million | $310.68 Million |
Alector Inc - Advanced Valuation Insights
This section examines the relationship between Alector Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.68 |
| Latest Market Cap to Assets Ratio | 0.59 |
| Asset Growth Rate (YoY) | -37.4% |
| Total Assets | $293.24 Million |
| Market Capitalization | $172.17 Million USD |
Valuation Analysis
Below Book Valuation: The market values Alector Inc's assets below their book value (0.59x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Alector Inc's assets decreased by 37.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Alector Inc (2016–2025)
The table below shows the annual total assets of Alector Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $293.24 Million | -37.38% |
| 2024-12-31 | $468.30 Million | -24.69% |
| 2023-12-31 | $621.83 Million | -21.05% |
| 2022-12-31 | $787.65 Million | -3.32% |
| 2021-12-31 | $814.66 Million | +66.85% |
| 2020-12-31 | $488.25 Million | +15.72% |
| 2019-12-31 | $421.91 Million | +36.83% |
| 2018-12-31 | $308.36 Million | +30.63% |
| 2017-12-31 | $236.06 Million | +336.25% |
| 2016-12-31 | $54.11 Million | -- |
About Alector Inc
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheim… Read more